TY - JOUR
T1 - Emerging Options for the Prevention and Management of Clostridioides difficile Infection
AU - Gonzales-Luna, Anne J.
AU - Carlson, Travis J.
AU - Garey, Kevin W.
N1 - Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Nature Switzerland AG.
PY - 2023/2
Y1 - 2023/2
N2 - Agents in development for the prevention or treatment of Clostridioides difficile infection can be split into three broad categories: antibiotics, microbiome restoration, and vaccines. Given the extensive list of agents currently in development, this narrative review will focus on agents that have progressed into late-stage clinical trials, defined as having a Phase III clinical trial registered on ClinicalTrials.gov. These agents include one antibiotic (ridinilazole), three live biotherapeutic products (LBPs) (CP101, RBX2660, and SER109), and two toxoid vaccines (PF06425090 and a second toxoid vaccine). As new prevention and treatment strategies enter the market, clinicians and administrators will need knowledge of these products to make rational decisions on how best to adopt them into clinical practice.
AB - Agents in development for the prevention or treatment of Clostridioides difficile infection can be split into three broad categories: antibiotics, microbiome restoration, and vaccines. Given the extensive list of agents currently in development, this narrative review will focus on agents that have progressed into late-stage clinical trials, defined as having a Phase III clinical trial registered on ClinicalTrials.gov. These agents include one antibiotic (ridinilazole), three live biotherapeutic products (LBPs) (CP101, RBX2660, and SER109), and two toxoid vaccines (PF06425090 and a second toxoid vaccine). As new prevention and treatment strategies enter the market, clinicians and administrators will need knowledge of these products to make rational decisions on how best to adopt them into clinical practice.
UR - http://www.scopus.com/inward/record.url?scp=85146380512&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146380512&partnerID=8YFLogxK
U2 - 10.1007/s40265-022-01832-x
DO - 10.1007/s40265-022-01832-x
M3 - Article
C2 - 36645620
AN - SCOPUS:85146380512
SN - 0012-6667
VL - 83
SP - 105
EP - 116
JO - Drugs
JF - Drugs
IS - 2
ER -